Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout

Dow Jones

04/23

By Elias Schisgall

Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.

Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.

Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.

The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.

Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.

Herbster previously led human resources and business operations at Sage Therapeutics.

They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said.

Nathalie Harroy, who currently serves as head of human resources, will also stay with the company.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

April 22, 2026 18:51 ET (22:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2629079968"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629079968\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629079968?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629079968","market":"sh","top_or_hot":-1,"title":"Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-23 06:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVA","symbol_name":"Inventiva S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629079968","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629079968","pubTimestamp":1776898260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.Herbster previously led human resources and business operations at Sage Therapeutics.They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVA":"Inventiva S.A.","BK4139":"生物科技"},"translate_title":"Inventiva在Lanifibranor第三阶段公布之前任命Malkomes为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n\n\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility. \n\n\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene. \n\n\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n\n\n  Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n\n\n  Herbster previously led human resources and business operations at Sage Therapeutics. \n\n\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n\n\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 18:51 ET (22:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}